Publicaciones en colaboración con investigadores/as de Clínica Universitaria de Navarra (23)

2024

  1. An automated network-based tool to search for metabolic vulnerabilities in cancer

    Nature Communications , Vol. 15, Núm. 1

  2. Epigenetic-based differentiation therapy for Acute Myeloid Leukemia

    Nature Communications, Vol. 15, Núm. 1

  3. PVR (CD155) epigenetic status mediates immunotherapy response in multiple myeloma

    Leukemia

  4. Rna-loaded nanoparticles for the treatment of hematological cancers

    Advanced Drug Delivery Reviews, Vol. 214

2013

  1. Long non-coding RNAs in haematological malignancies

    International Journal of Molecular Sciences, Vol. 14, Núm. 8, pp. 15386-15422

2012

  1. Epigenetic regulation of miRNA genes in acute leukemia

    Leukemia, Vol. 26, Núm. 3, pp. 395-403

2011

  1. NPM1 gene deletions in myelodysplastic syndromes with 5q- and complex karyotype

    Haematologica, Vol. 96, Núm. 5, pp. 784

2010

  1. Epigenetic regulation of the non-canonical Wnt pathway in acute myeloid leukemia

    Cancer Science, Vol. 101, Núm. 2, pp. 425-432

2009

  1. Epigenetic down-regulation of BIM expression is associated with reduced optimal responses to imatinib treatment in chronic myeloid leukaemia

    European Journal of Cancer, Vol. 45, Núm. 10, pp. 1877-1889

  2. Epigenetic silencing of the tumor suppressor microRNA Hsa-miR-124a regulates CDK6 expression and confers a poor prognosis in acute lymphoblastic leukemia

    Cancer Research, Vol. 69, Núm. 10, pp. 4443-4453

2008

  1. BCR-ABL1-induced expression of HSPA8 promotes cell survival in chronic myeloid leukaemia

    British Journal of Haematology, Vol. 142, Núm. 4, pp. 571-582

  2. Down-regulation of hsa-miR-10a in chronic myeloid leukemia CD34+ cells increases USF2-mediated cell growth

    Molecular Cancer Research, Vol. 6, Núm. 12, pp. 1830-1840

  3. Mecanismos de resistencia primaria al tratamiento con imatinib

    Medicina Clinica Monografias, Vol. 9, Núm. 8, pp. 3-7

  4. Repetitive DNA hypomethylation in the advanced phase of chronic myeloid leukemia

    Leukemia Research, Vol. 32, Núm. 3, pp. 487-490

2007

  1. Epigenetic regulation of PRAME gene in chronic myeloid leukemia

    Leukemia Research, Vol. 31, Núm. 11, pp. 1521-1528

  2. WNT5A, a putative tumour suppressor of lymphoid malignancies, is inactivated by aberrant methylation in acute lymphoblastic leukaemia

    European Journal of Cancer, Vol. 43, Núm. 18, pp. 2736-2746

2006

  1. ASPP1, a common activator of TP53, is inactivated by aberrant methylation of its promoter in acute lymphoblastic leukemia

    Oncogene, Vol. 25, Núm. 13, pp. 1862-1870

  2. Abnormal methylation of the common PARK2 and PACRG promoter is associated with downregulation of gene expression in acute lymphoblastic leukemia and chronic myeloid leukemia

    International Journal of Cancer, Vol. 118, Núm. 8, pp. 1945-1953

  3. Downregulation of DBC1 expression in acute lymphoblastic leukaemia is mediated by aberrant methylation of its promoter

    British Journal of Haematology, Vol. 134, Núm. 2, pp. 137-144

2005

  1. Coexistence of different clonal populations harboring the b3a2 (p210) and e1a2 (p190) BCR-ABL1 fusion transcripts in chronic myelogenous leukemia resistant to imatinib

    Cancer Genetics and Cytogenetics, Vol. 160, Núm. 1, pp. 22-26